Department of Dermatology, University Clinic of Navarra / Fundación Piel Sana, ES-28008 Madrid, Spain.
Acta Derm Venereol. 2021 Nov 24;101(11):adv00602. doi: 10.2340/actadv.v101.544.
Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the "real-life" results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1-1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3-6.1), being constant over time (0-5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.
随机研究评估 Mohs 显微外科手术在基底细胞癌和鳞状细胞癌中的疗效受到方法学和伦理问题以及缺乏长期随访期的限制。本研究展示了一项针对基底细胞癌和鳞状细胞癌的全国性 7 年队列研究的“真实世界”结果,这些患者接受了 Mohs 显微外科手术治疗。在 22 个西班牙中心进行了一项前瞻性队列研究(2013 年 7 月至 2020 年 2 月),并进行了包括患者、肿瘤、手术和随访特征的多变量分析。共招募了 4402 例接受基底细胞癌随访 12111 人年,371 例接受鳞状细胞癌随访 915 人年。复发的危险因素包括年龄、非原发性肿瘤、两种肿瘤的更多分期或未完成手术以及鳞状细胞癌的免疫抑制。基底细胞癌的复发率为每 100 人年 1.3 例(95%置信区间 1.1-1.5),鳞状细胞癌为 4.5 例(95%置信区间 3.3-6.1),且随时间保持不变(0-5 年)。总之,至少在前 5 年应同样强烈地进行随访策略,特别要关注鳞状细胞癌(特别是在免疫抑制患者中)、老年患者、非原发性肿瘤以及需要更多分期或未完成手术的患者。